Mirum says Phase 3 EXPAND trial of Livmarli meets primary endpoint
MIRM•Mirum Pharmaceuticals said its Phase 3 EXPAND trial of LIVMARLI met its primary endpoint, showing improved cholestatic itch versus placebo in ultra-rare cholestatic liver diseases. The company plans a U.S. supplemental NDA filing in the first half of 2027.
1. Trial results
The Phase 3 EXPAND trial met its primary endpoint, showing improved cholestatic itch versus placebo. Secondary measures also favored LIVMARLI, including results among biliary atresia patients with a native liver; safety was consistent with prior experience, with no new safety signals reported.
2. Planned filing
Mirum plans to file a U.S. supplemental NDA in the first half of 2027 and said results would be discussed on an investor call.
